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Poster Session II 105and expanded with different dominant responses detected in differ-
ent donors. In conclusion, we have developed a method for the in-
vitro induction and isolation of functional CMV-specific CD81 T
cells from CMV- donors. This may allow the treatment of serious
CMV-related complications in CMV1 patients transplanted with
a CMV- donor.283
THE USE OF SIROLIMUS COMBINED WITH TACROLIMUS AND LOW-
DOSE METHOTREXATE TO PREVENT GRAFT-VERSUS-HOST DISEASE
FOLLOWING UNRELATED DONOR HEMATOPOIETIC STEM CELL TRANS-
PLANTATION
Nakamura, R.1, Rodriguez, R.1, Palmer, J.2, Nademanee, A.1, Sun, J.1,
Senitzer, D.1, Pullarkat, V.1, Aljitawi, O.1, Zain, J.1, Snyder, D.1,
Parker, P.M.1, Forman, S.J.1. 1City of Hope National Medical Center,
Duarte, CA; 2City of Hope National Medical Center, Duarte, CA.
The use of sirolimus (siro) combined with tacrolimus (tacro) and
low-dose methotrexate (MTX) recently showed a promising result
in preventing acute GVHD after unrelated donor hematopoietic
stem cell transplantation (MUD-HCT) (Antin et al. Blood 2003).
We studied this approach in 77 patients (female 5 30, male 5 47)
who received a MUD-HCT after full-intensity conditioning
(TBI-VP16: 17, TBI-Cy: 10, BuCy: 3, BEAM: 2) or reduced inten-
sity conditioning (FluMel: 45) from April 2005 to March 2007. Pa-
tient age ranged from 19 to 67 (median 46). The cohort consisted of
20 patients with AML, 19 with ALL, 15 with NHL, 8 with MDS, 5
with MPD, 4 with HD, 3 with CML, and 2 with CLL. Twenty-
seven of 77 patients had low-risk disease (1st/2nd CR, CML-CP,
or MDS-RA). Patients received a bone marrow (n5 15) or periph-
eral blood stem cell graft (n5 62). GVHD prophylaxis consisted of
tacro, siro, and MTX 5 mg/m2 for 3–4 days. High-resolution (HR)
molecular HLA typing was performed for class I and II. Forty-two
pairs were in HRmolecular match in all 10 antigens (HLA-A, B, C,
DR, and DQ). Lack of iKIRL was found in 50 pairs.
After a median follow up of 13 months, 50 are alive. The 1-year
probabilities of overall survival (OS), disease-free survival, relapse,
and non-relapse mortality were 60.6% (95%CI: 52.6–67.6),
55.9% (95%CI: 48.8–62.5), 15.0% (95%CI: 8.5–25.7), and 25.4%
(95%CI: 17.9–35.3), respectively. Severe thrombotic microangiop-
athy was observed in two patients and was reversible.
Acute GVHD grade II-IV and III-IV occurred in 46 (60%) and
17 (22%), respectively. Of 46 patients evaluable, 26 (56.5%) devel-
oped chronicGVHD (225extensive, 45limited).Multivariate anal-
ysis for acute GVHD (II-IV) demonstrated a significantly increased
risk with older age ($ median) (HR 1.9[1.0–3.5], p 5 0.05) and
a trend for patients without lack of iKIRL (HR 1.9[0.9–3.8], p 5
0.08). Degree of HLA match, conditioning regimen, disease risk,
gender mismatch, stem cell source, or CMV serostatus had no sig-
nificant impact on acute GVHD. Reduced intensity conditioning
was associated with better OS (76%) compared with full-intensity
conditioning (38%, p5 0.01), which remained significant in multi-
variate analysis (HR: 0.4[0.2–0.8], p 5 0.02).
In summary, our results show the combination of siro, tacro, and
low-dose MTX is associated with an acute GVHD rate comparable
to our historic data afterMUD-HCT, and associated with a promis-
ingOSwhen combinedwithFluMel reduced-intensity conditioning.284
GRAFT REJECTION AS A TYPE I IMMUNE RESPONSE AMENABLE TO
MODULATION BY TYPE II DONOR T CELLS VIA AN ‘‘INFECTIOUS’’ MECH-
ANISM
Mariotti, J., Foley, J., Amarnath, S., Buxhoeveden, N., Ryan, K.,
Costanzo, C.M., Fowler, D.H. NCI/NIH, Bethesda, MD.
We investigated themechanism(s) whereby rapamycin-generated
donor Th2 cells (Th2R cells) prevent graft rejection after allogeneic
bone marrow transplantation (BMT). Analogous to Th1/Th2 cyto-
kine balance in GVHD, we hypothesized that host-versus-graft re-
activity (HVGR) may involve type I cells amenable to inhibition by
type II cells. Fully MHC-disparate BMT was performed: [BALB/
c(H-2 d) into B6(H-2 b)] or [B6-into-BALB/c]; lethal host irradia-
tion (XRT;1050 cGy); and post-XRT add-back of host T cells (0.1 106). Wild-type (WT) or Th1/Tc1 host T cells mediated rejec-
tion (5/5 and 10/10 mice, respectively); in contrast, host Th2/Tc2
cells yielded full donor chimerism (10/10 mice). STAT1 signaling,
which dictates Th1 differentiation, was required for rejection, as
post-XRT add-back of STAT1 knockout (KO) host T cells yielded
full donor engraftment (5/5 mice). HVGR was quantified by cyto-
kine-capture flow cytometry: host T cells were harvested post-
BMT, stimulated with donor APC, and allospecific host T cells
was enumerated. Mice receiving WT or Th1/Tc1 host T cells
had increased post-BMT allospecific CD41 and CD81 T cells se-
creting IFN-g(cohort [C] #3.C#2; p\0.05; C#4.C#2; p\0.05).
In contrast, Th2/Tc2 or STAT1 KO host T cell add-back yielded
nominally increased alloreactive host T cells (C#3 and C#4.C#5,
p\0.02; C#3.C#6, p\0.002). These results suggested that donor
Th2R cells may prevent rejection by reducing host Th1-type differ-
entiation and promoting host Th2-type differentiation rather than
by mediating host T cell clonal deletion. To evaluate this, allospe-
cific 2C TCR transgenic T cells were utilized as host T cell add-
back; BMT was performed 6 donor Th2R cells. Low-dose donor
Th2R cells relative to host 2CTCR transgenic cells (200:1) resulted
in rejection (5/5 mice); 2C cell expansion and alloreactivity were
nominally decreased by this Th2R cell dose. However, high-dose
Th2R cells (1000:1) promoted full donor engraftment (7/10
mice); rejection prevention was associated with reduced expansion
but not total elimination of 2C cells and reduced 2C cell IFN-g al-
lospecificity (C#11\C#10, p5 .008). Furthermore, in this cohort,
cytokine profile of purified post-BMT 2C cells was analyzed: the
cells were skewed towards a Th2 phenotype (reduced IL-2, IFN-
g; increased IL-4, IL-10). Taken together, Th2R cells prevent re-
jection by a mechanism that promotes type II cytokine ‘‘infectious
transplantation tolerance’’ without allospecific clonal deletion.
Role of Th1/Tc1, Th2/Tc2, STAT1 KO in Graft Rejection: Abrogation
of 2C Cell Rejection by Donor Th2R Cell Infusion
Alloreactive AlloreactiveModel #1
B6/BALB/c
(Inocula)Host CD4
Cells (# CD41
IFN-g 1 T cells; 
103/spleen)Host CD8
Cells (# CD81
IFN-g 1 T cells; 
103/spleen)% Donor
CellsCohort1 BM 1.8 ± 1.8 0 ± 0 88 ± 22 Host T 5.1 ± 1.6 3.1 ± 2.2 -3 BM 1 Host T 772 ± 256 653 ± 218 0.8 ± 04 BM 1 Host T1 2129 ± 723 1787 ± 574 0.8 ± 05 BM 1 Host T2 91 ± 31 22.2 ± 6.6 10 ± 2Model #2
BALB/c/B6
(Inocula)1 BM 0.1 ± 0.1 0.5 ± 0.2 54 ± 52 Host T 24 ± 12 7 ± 1 -3 BM 1 Host T 1249 ± 285 3927 ± 555 1.6 ± 0.36 BM 1 Host T
STAT1 KO48 ± 43 68 ± 54 61 ± 6Model #3
BALB/c/B6
(2C TCR Host
Add-back)Absolute # of
2C TCR Host
T cells
(103/spleen)Absolute # of
2C TCR IFN-g
alloreactive
host T cells
(103/spleen)% Donor
Cells7 BM - - 90 ± 28 Host T 307 ± 56 77 ± 18 -9 BM 1 Host T 3656 ± 1189 817 ± 226 0.4 ± 0.110 BM 1 Host T 1 Donor
Th2R (200:1 ratio)884 ± 144 525 ± 140 1.7 ± 0.311 BM 1 Host T 1 Donor
Th2R (1000:1 ratio)152 ± 43 30 ± 17 92.6 ± 1.2285
APPLYING THE HEMATOPOIETIC CELL TRANSPLANTATION-COMOR-
BIDITY INDEX (HCT-CI) IN MYELOABLATIVE MUD TRANSPLANTS PRE-
DICTS NRM AND OS USING A MODIFIED 2-GROUP SCORING SYSTEM
Kovacsovics, T.1,2, Park, B.2, Hayes-Lattin, B.1,2, Dunn, A.1,
Curtin, P.T.1,2, Leis, J.F.1,2, Epner, E.E.1,2, Meyers, G.1,2,
Maziarz, R.T.1,2. 1OHSU, Portland, OR; 2OHSU, Portland, OR.
106 Poster Session IIBackground: The HCT-CI is a comorbidity score adapted to
hematopoietic cell transplantation, which has identified 3 risk
groups with increased non-relapse mortality (NRM) and lower
overall survival (OS) (Blood 2005;106:2912). We determined the
HCT-CI score in a cohort of patients who underwent myeloabla-
tive MUD transplantation in an single institution trial. Methods:
The analysis included all patients undergoing MUD transplant
from 1996–2006 who received a 3-drug GVHD prophylaxis regi-
men. Comorbidities were obtained by retrospective chart review
and scored according to the HCT-CI score. Results: 150 patients
(median age 40) were included, with 38% low-, 34% intermediate-
and 28% high-risk disease, per CIBMTR classification. Diagnoses
included acute leukemia in 50%, MDS in 12%, CML in 15%,
and lymphoma in 18%. Conditioning regimens were Cy-TBI in
64% and Bu-Cy in 21%. HCT-CI scores of 0, 1–2 or $3 were
found in 17%, 30% and 53% of patients. The majority of comor-
bidities were pulmonary (72%). Day 100 and 5-year OS were 82.7
and 33%, with a 23% and 50.4% cumulative incidence of NRM.
Five year relapse-related mortality was 15.8%. No statistically
significant differences in NRM or OS were detected using the
HCT-CI grouping of 0, 1–2 and $3. Unadjusted hazard ratio
(HR) for inferior survival were 0.9 (CI 0.47–1.85, P 5 .79) and
1.65 (CI 0.885–3.090, P5 .11) for scores 1–2 and$3, respectively.
We determined an alternate prognostic model based on 2 groups.
Statistical modeling separated patients with a score of 0–3 (n 5
97, 64%) and $4 (n 5 53, 35.6%), with a 3 month and 5 year OS
of 84% and 45% versus 52% and 10%, respectively (P\ .0001).
Cumulative incidence of day 100 and 5-year NRM was 16% and
38% versus 43% and 73%, respectively. UnadjustedHR for inferior
survival was 2.77 (CI 1.816–4.225, P\ .0001) for a score of$4. By
multivariate analysis, only the HCT-CI score (P\ .0001) and the
disease risk per CIBMTR (P 5 .0058) were predictive of OS and
NRM, but not age, CMV status, sex- or HLA-mismatch, or regi-
men. Conclusions: Although the HCT-CI score was predictive
of NRM and OS in this high-risk cohort, we were unable to detect
statistically significant differences between the 3 risk groups defined
in the original score. A modified 2-group scoring system of 0–3 and
$4, respectively, identified a low-risk and a high-risk group. This
simplified, 2-tiered scoring system will have utility in clinical deci-
sion-making and in defining patients eligible for clinical trials.286
LIPOPOLYSACCHARIDE BINDING PROTEIN PROMOTER VARIANTS IN-
FLUENCE THE RISK FOR GRAM-NEGATIVE BACTEREMIA AND MORTAL-
ITY AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION
Chien, J.W., Boeckh, M., Hansen, J.A., Clark, J.G. Fred Hutchinson
Cancer Research Center, Seattle, WA.
Lipopolysaccharide binding protein (LBP) function is dependent
upon circulating LBP levels. Disturbance of LBP transcription reg-
ulation may influence the risk for clinical events. We comprehen-
sively assessed the LBP sequence and identified three haplotype
tagging single nucleotide polymorphisms (SNPs) for our studies.
Using a nested case control design, we assessed whether genetic var-
iation in the LBP gene influences the risk for Gram-negative (GN)
bacteremia after allogeneic hematopoietic cell transplantation
(HCT), then confirmed the associations by prospectively assessing
association with an intermediate phenotype (circulating LBP levels)
and a secondary clinical phenotype (mortality). Presence of the SNP
6878 C allele among patients was associated with a two-fold higher
risk for GN bacteremia (odds ratio 2.22, p5 0.001). SNP 6878 was
in strong linkage disequilibrium with three SNPs in the LBP pro-
moter, one of which was SNP 6878 (r25 0.8), located in a promoter
CAAT box. The SNP 1683 C allele was associated with higher me-
dian circulating LBP levels (TT 10.86 6 0.68 mg/ml; TC 13.86 6
1.51 mg/ml; CC 20.66 6 5.89 mg/ml; p 5 0.002) and a three-fold
increase in mortality risk (hazard ratio 3.30, p 5 0.001). These
data suggest that genetic variation in the LBP promoter variation
likely influences the risk for developing GN bacteremia and death
after HCT.287
HEMATOPOIETIC CELL TRANSPLANTATION (HCT) FOR CHEMORADIO-
THERAPY-RELATED MYELODYSPLASTIC SYNDROME AND ACUTE LEU-
KEMIA: A SINGLE-CENTER ANALYSIS OF 47 PATIENTS
Yokoyama, H., Fukuda, T., Kobayashi, Y., Kim, S.-W., Maruyama, D.,
Mori, S.-I., Watanabe, T., Tanosaki, R., Tajima, K., Tobinai, K.,
Takaue, Y. National Cancer Center Hospital, Tokyo, Japan.
Purpose: To examine the value of allogeneic HCT in the treat-
ment of therapy-related myelodysplastic syndrome/acute leukemia
(t-MDS/t-AL) which develops after previous exposure to chemo-
therapy (CT) or radiotherapy. Patients and Methods: We retro-
spectively analyzed the data of 47 patients who were treated at
our institution between 1996 and 2007. The primary diseases in-
cluded malignant lymphoma (n 5 17), breast cancer (n 5 13) and
other solid tumors (n5 17). The median interval between the diag-
nosis of the primary disease and the onset of t-MDS/t-AL was 3.9
years (range, 0.6–18.7). Twenty-five patients had AML, 5 ALL, 1
biphenotypic acute leukemia, and 16 MDS. Results: Thirty-three
patients received disease-adapted CT, with a response rate of
73%, while 14 patients were elected to receive no interventions
due to an indolent clinical course such as MDS-RA (n 5 13).
With a median follow-up of surviving patients of 1.9 years (range,
0.05–10.5) after the diagnosis of t-MDS/t-AL, the 3-year OS for
all patients was 55%. Twenty-seven patients (median age, 47 years:
range, 3–63) underwent allogeneic HCT from related (n 5 12) or
unrelated (n 5 15) donors after myeloablative (n 5 18) or re-
duced-intensity (n 5 9) conditioning regimens. The sources of
stem cells were BM in 15 patients, PBSC in 10, and CB in 2. At
the time of HCT, 18 t-MDS/t-AL were in CR, 1 was in non-CR,
and 8 had untreated t-MDS. Twenty patients (43%) did not un-
dergo HCT due to various reasons, including age older than 65
years (n 5 11), indolent clinical course (n 5 4), progression of the
primary disease (n 5 4) or t-AL (n 5 3), and patient refusal (n 5
2). The 3-year OS was significantly better in patients who received
HCT than in those who did not (71% vs 31%; P 5 0.018). TRM
after HCT was 15%. The 3-year OS was better in those who
achieved CR after initial therapy for t-MDS/t-AL than in those
who did not (74% vs 30%; P 5 0.002). A multivariate analysis re-
vealed that HCT was associated with a significantly better OS,
even after adjusting for age and other significant prognostic factors
including achievement of CR in t-MDS/AL, cytogenetic risk group,
and an interval between the diagnosis of primary disease and t-
MDS/t-AL of longer than 3 years.Conclusion:Although this study
is contaminated by a selection bias, it still appears that HCT was an
effective therapeutic option for patients with t-MDS/t-AL, espe-
cially when patients were in CR.These results support a prospective
study to examine the value of upfront HCT.288
HEALTHY ALLOGENEIC RELATED DONORS OF PERIPHERAL HAEMATO-
POIETIC PROGENITORS: A LONG-TERM PROSPECTIVE STUDY
Tassi, C.1, Arpinati, M.2, Giudice, V.1, Bontadini, A.1. 1Sant’Orsola-
Malpighi Policlinic, Bologna, Italy; 2Sant’Orsola-Malpighi Policlinic,
Bologna, Italy.
One hundred and thirty six healthy donors who underwent
aphaeresis collections after G-CSF stimulation have been included
in a surveillance protocol for a provisional period of ten years. Once
a year, they are required to send aWBC, Hb and platelets count re-
port and clinical information to our Service. To date, the mean ob-
servation time is 46(4–120) months. Fifty out of the 136 donors
show a follow-up longer than 60 months. As previously described
(1), at day 114 after G-CSF administration, a moderate neutrope-
nia or lymphocytopenia, have been documented in 32 and 20 sub-
jects, respectively. Moreover, a mild thrombocytopenia has been
diagnosed during the G-CSF administration in 52 donors. After
a five years period of observation, a persistent, slight reduction of
circulating neutrophils or lymphocytes has been detectable in 5/
32 or 5/20 donors, without clinical relevance. As regards clinical
data, 1 case of MGUS, Insipid Diabetes, Autoimmune Thyroiditis,
Multiple Sclerosis, Intestinal Multiple Polyps and Allergy to certain
food, were the main diseases reported by six donors. Four donors
